Protalix Biotherapeutics, Inc. Receives FDA IND Clearance to Initiate a Phase I/II Study of Fabry Disease Patients With PRX-102, a Modified Enzyme Replacement Therapy

Published: Aug 13, 2012

CARMIEL, Israel, Aug. 13, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate clinical trials of PRX-102. The Company plans to commence enrollment of Fabry disease patients for a phase I/II trial in the fourth quarter of 2012.

Back to news